MedTrace Logo

An Efficacy and Safety Study of Theraflu Day Powder as Oral Solution for Cold and Flu

NCT02678234 · Status: WITHDRAWN · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2018-03-12

No results posted yet for this study

Summary

The purpose of the study is to assess the short term efficacy of the Theraflu Aktiv powder for oral solution in the Russian population as compared to an untreated group to support the indication of "Short term relief of the symptoms of colds, chills and influenza, including mild to moderate pain, fever and nasal congestion".

Conditions

  • Infections, Respiratory Tract

Interventions

DRUG

Paracetamol, phenylephrine HCl, and vitamin C

One sachet is provided for each participant randomized to the Theraflu Aktiv powder for oral solution

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-02-01
Primary Completion
2017-04-01
Completion
2017-04-01

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02678234 on ClinicalTrials.gov